|
|
Please type responses here: |
|
First Name:
|
|
|
Last Name:
|
|
|
Email Address:
|
|
|
Retype Email Address:
|
|
|
Title:
|
|
|
Institution:
|
|
|
Phone Number:
|
|
|
City:
|
|
|
State/Province:
|
|
|
Postal/Zip Code:
|
|
|
Country:
|
|
|
What topics would you like to see covered in future POC Group Webinars?
|
|
|
Overall, how would you rate your satisfaction with this Point of Care Web Meeting?
|
Extremely satisfied
Very satisfied
Somewhat satisfied
Dissatisfied
|
|
Your feedback helps your webinar producers and sponsors improve the overall quality of their products and services.
|
|
I would like to know more about (choose all that apply):
|
Adding a device type to RALS
Knowing more about operator management tools
Scalable feature sets
The Configurable Device Driver tool
|
|
What current data management system(s) are you using? Choose all that apply:
|
Abbott PrecisionWeb™
GEMweb® Plus
Orchard® Point-of-Care
Radiometer AQURE
Radiometer Radiance
RALS™ Connectivity System
Roche cobas® IT 1000 / cobas® infinity POC
SIEMENS POCcelerator™
SIEMENS RapidComm®
SIEMENS UniPOC™
Telcor QML®
None
Other
|
|
If you chose ‘other’ in the question above, please list your current data management system(s):
|
|
|
Do you currently use Cepheid tests?
|
Yes
No
|
|
Are you looking to add any new CLIA waived molecular tests this year?
|
Yes
No
|
|
Would you like to be contacted to learn more about Cepheid's POC solutions?
|
Yes
No
|
|
Which of the following best describes natriuretic peptide (BNP or NT-proBNP) testing in your health system?
|
Currently offer point of care natriuretic peptide tests in our hospital setting
Currently offer point of care natriuretic peptide tests in our outpatient clinics
Currently offer point of care natriuretic peptide tests in both outpatient clinics and hospital setting
None, this is offered as a send-out test or run in the lab not POC
N/A – I don’t oversee POC tests outside of the hospital
|
|
Are you open to learning more about how the LumiraDx Platform and microfluidic test technology might fit into your decentralized lab settings?
|
Yes
No
N/A
|
|
Has your urinalysis program been standardized?
|
Yes
No
Not sure
|
|
What priorities matter most to your organization concerning point-of-care urinalysis? Please select all that apply:
|
Clinical precision
Regulatory compliance
User-friendliness
Connectivity and integration
Workflow optimization
|
|
Would you be interested in learning how the CLIA-waived CBC can help reduce lab send outs?
|
Yes
No
|
|
Will you be adding CLIA-waived tests to your practices within next 6 months?
|
Yes
No
|
|
Would you like to receive ASCLS PACE credit for this session, program number 174-018-24? (If no, you do not need to complete the following questions.)
|
Yes
No
|
|
To receive ASCLS PACE credit (PACE Program number 174-018-24, California Agency #0001) for "Point of Care Testing: Cost vs. Convenience" presented on September 18, 2024, you will be required to complete the following program evaluation.
|
|
If the following is true, please answer "Yes": I have attended the full instructional time for this program. I understand that completion of the program is necessary to receive the contact hours awarded for the program.
|
Yes
No
|
|
SPEAKER RATING
|
|
To what extent was the speaker knowledgeable, organized and effective during the presentation? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
To what extent did the speaker clarify and focus on the stated objectives? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
To what extent were the speaker's teaching methods & aids appropriate & effective? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
OBJECTIVES RATING:
To what extent was each objective achieved?
|
|
Describe the one clear clinical reason to perform lab tests at POCT. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Identify how lab testing impacts health screening, management of peri-acute conditions and chronic disease management. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Discuss more about the relationship between MACRA and in office lab testing. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Explain information on lab testing and morbidity/mortality for the 10 leading causes of death in the US. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Assess how utilization management influences test selection. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
PROGRAM CONTENT RATING
|
|
To what extent did the program content relate to the program's objectives? (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Rate the contribution of this session to your overall knowledge of this subject. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Rate your overall degree of satisfaction with this session. (Rate on scale from 1 - 5 with 1 being the lowest and 5 being the highest)
|
1
2
3
4
5
|
|
Comments:
|
|
|
Thank you for attending this PACE approved program and completing this evaluation. Questions? Call Whitehat Communications at 434 202 8365.
|
|
|
